Global Leukapheresis Market Insights Forecasts to 2032

• The Global Leukapheresis Market Size was valued at USD 70.60 Million in 2022.
• The Market Size is Growing at a CAGR of 8.3% from 2022 to 2032
• The Worldwide Leukapheresis Market Size is expected to reach USD 156.71 Million by 2032
• Asia-Pacific is expected To Grow fastest during the forecast period

 

Get more details on this report -

Request Free Sample PDF

 

The Global Leukapheresis Market Size is expected to reach USD 156.71 Million by 2032, at a CAGR of 8.3% during the forecast period 2022 to 2032.

 

Market Overview

Leukapheresis is a medical procedure designed to selectively remove and concentrate white blood cells (leukocytes) from a patient's bloodstream. This therapeutic technique is primarily used in the treatment of various hematological disorders, such as leukemias and lymphomas, as well as for controlling high white blood cell counts in certain autoimmune diseases. During the procedure, blood is drawn from the patient and passed through a specialized machine that separates white blood cells from the rest of the blood components. The machine then returns the remaining blood components back to the patient's circulation. By reducing the number of abnormal or excessive leukocytes, leukapheresis helps alleviate symptoms, prevent organ damage, and manage the underlying condition.

 

Report Coverage

This research report categorizes the market for leukapheresis market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the leukapheresis market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the leukapheresis market.

 

Driving Factors

The leukapheresis market is driven by several factors that contribute to its growth and increasing adoption in various medical applications, the rising prevalence of hematological disorders, such as leukemia and lymphoma, has significantly boosted the demand for leukapheresis procedures as an effective therapeutic option. The increasing prevalence of autoimmune diseases with elevated white blood cell counts has further driven the market. Moreover, technological advancements in leukapheresis procedures and related equipment have improved the efficiency and safety of the process, leading to enhanced patient outcomes and wider acceptance among healthcare providers. The development of more sophisticated and automated leukapheresis devices has streamlined the treatment process, making it more accessible and reducing the need for highly specialized personnel. Furthermore, a growing aging population, which is more susceptible to hematological disorders, has created a larger pool of potential patients, driving the demand for leukapheresis procedures. Additionally, the increasing awareness among both healthcare professionals and patients about the benefits of leukapheresis in managing certain conditions has also contributed to market growth. The expanding scope of leukapheresis applications, such as in stem cell transplantation and cell-based therapies, has opened up new avenues for market expansion. As researchers and medical practitioners explore the potential of leukapheresis in various other therapeutic areas, the market is expected to witness further growth.

 

Restraining Factors

The leukapheresis market also faces certain restraints that could hinder its growth and widespread adoption. One significant restraint is the high cost associated with leukapheresis procedures and equipment, which may limit accessibility for patients in lower-income regions. Additionally, the requirement for specialized facilities and trained personnel to perform the procedure could create logistical challenges, especially in remote or underserved areas. Moreover, the potential risk of adverse reactions or complications during leukapheresis may raise concerns among patients and healthcare providers, impacting its acceptance. Regulatory complexities and ethical considerations related to cell-based therapies and stem cell transplantation may also pose obstacles to the market's expansion.

 

Market Segmentation

• In 2022, the disposables segment accounted for around 62.7% market share

On the basis of the offering, the global leukapheresis market is segmented into devices and disposables. The disposables segment held the largest share in the leukapheresis market for several reasons. Disposable leukapheresis kits and components are widely used in procedures as they offer convenience, reduced risk of contamination, and simplified handling. These single-use products eliminate the need for extensive cleaning and sterilization, ensuring patient safety and procedural efficiency. Additionally, the cost-effectiveness of disposables compared to reusable equipment makes them a preferred choice for healthcare facilities, especially in resource-constrained regions. The growing trend of using disposable products in medical settings, coupled with advancements in manufacturing techniques, has further propelled the disposables segment's dominance in the leukapheresis market.

 

• In 2022, the research segment accounted for around 70.8% market share

Based on the application, the global leukapheresis market is segmented into therapeutic and research. The research segment held the largest share in the leukapheresis market due to several key factors. Leukapheresis plays a crucial role in various research applications, such as drug development, immunology, and cell-based therapies. Researchers heavily rely on leukapheresis to isolate specific white blood cells for in-depth study and experimentation. Additionally, the increasing focus on personalized medicine and the use of leukapheresis in generating patient-specific cellular therapies have further boosted the demand for leukapheresis in the research domain. The growing number of research institutions, academic collaborations, and funding initiatives have also contributed to the research segment's dominant position in the market.

 

• The blood component providers & blood centers segment is expected to grow at a higher CAGR of around 8.5% during the forecast period

Based on the end-user, the global leukapheresis market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & transfusion centers, and blood component providers & blood centers. The blood component providers and blood centers segment is anticipated to experience higher growth in the leukapheresis market during the forecast period for several compelling reasons. These entities play a crucial role in the collection, processing, and distribution of blood components, including leukapheresis-derived products. As the demand for leukapheresis procedures increases, blood centers and component providers are expected to witness greater adoption of leukapheresis technology to meet the rising demand for specific white blood cell products. Moreover, advancements in leukapheresis techniques have improved the efficiency and safety of the process, making it an attractive option for blood centers to enhance their offerings and better serve patients' medical needs.

 

Regional Segment Analysis of the Leukapheresis Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America dominated the market with more than 45.8% revenue share in 2022.

 

Get more details on this report -

Request Free Sample PDF

 

North America held the largest share in the leukapheresis market due to a high prevalence of hematological disorders, such as leukemia and lymphoma, which drives the demand for leukapheresis procedures. Additionally, North America has a well-established healthcare infrastructure, with advanced medical facilities and trained professionals, contributing to the wider adoption of leukapheresis. Moreover, the presence of key market players and ongoing research and development activities in the region further support market growth.

 

Asia-Pacific is anticipated to experience the fastest growth in the leukapheresis market during the forecast period due to several compelling factors. The region's large and aging population, coupled with a rising prevalence of hematological disorders and autoimmune diseases, is driving the demand for leukapheresis procedures. Improving healthcare infrastructure and increasing investments in the healthcare sector are also contributing to the market's growth.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global leukapheresis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Companies:

• Asahi Kasei Medical Co. Ltd.
• Fresenius SE & CO. KGaA
• Haemonetics Corporation
• Macopharma
• Terumo BC T Inc.
• B. Braun Melsungen AG
• Stemcell Technologies Inc.
• Precision Medicine Group LLC
• BiolVT LLC
• Kaneka Corporation

 

Key Target Audience

• Market Players
• Investors
• End-Users
• Government Authorities 
• Consulting and Research Firm
• Venture Capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In February 2022, Cryoport Inc. has formed a strategic alliance with Cell Matters SA to provide the life sciences sector with end-to-end cryopreservation services for leukapheresis-derived treatments that support both autologous and allogeneic cell therapies.

 

• In July 2021, Terumo Blood and Cell Technologies has launched a direct offering to clinicians for extracorporeal photopheresis immunotherapy (ECP) operations performed at the patient's bedside. Spectra Optia's capability has been extended by the firm. These devices may now be used to execute the UVA PIT System ECP as a functionally closed, online, multistep system with mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) procedures.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2032. Spherical Insights has segmented the global leukapheresis market based on the below-mentioned segments:

 

Leukapheresis Market, By Offering

• Devices
• Disposables

 

Leukapheresis Market, By Application

• Therapeutic
• Research

 

Leukapheresis Market, By End-User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospitals & Transfusion Centers
• Blood Component Providers & Blood Centers

 

Leukapheresis Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa